Isoalloxazine (e.g., Riboflavins, Vitamin B2, Etc.) Patents (Class 514/251)
  • Patent number: 10280176
    Abstract: Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: May 7, 2019
    Assignee: Nerviano Medical Sciences S.R.L.
    Inventors: Gabriella Traquandi, Maria Gabriella Brasca, Roberto D'Alessio, Paolo Polucci, Fulvia Roletto, Anna Vulpetti, Paolo Pevarello, Achille Panzeri, Francesca Quartieri, Ron Ferguson, Paola Vianello, Daniele Fancelli
  • Patent number: 9822391
    Abstract: The present invention provides methods for assessing efficacy of a methotrexate (MTX) dosing regimen in a patient.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: November 21, 2017
    Inventor: Thierry Dervieux
  • Patent number: 9492449
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administering a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and administering at least one additional therapeutic agent.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: November 15, 2016
    Assignee: Gilead Calistoga LLC
    Inventors: W. Michael Gallatin, Roger G. Ulrich, Neill A. Giese, Brian Lannutti, Langdon Miller, Thomas M. Jahn
  • Patent number: 9399625
    Abstract: (A1) A class of acridone compounds has been discovered that exhibits chemosensitizing and antiparasitic activity. Described herein are pharmaceutical compositions and methods for their use to treat parasitic infections, such as malaria and toxoplasmosis, and to sensitize resistant cells, such as multidrug resistant cells to other therapeutic agents. The pharmaceutical compositions and methods may also be used to treat and/or prevent psychotic diseases such as schizophrenia.
    Type: Grant
    Filed: February 16, 2015
    Date of Patent: July 26, 2016
    Assignees: Oregon Health & Science University, The United States of America
    Inventors: Michael K. Riscoe, Rolf W. Winter, Jane X. Kelly, David J. Hinrichs, Martin J. Smilkstein
  • Patent number: 9322831
    Abstract: The invention encompasses methods for treating or preventing diseases and disorders associated abnormal cell growth, for example, treating or preventing cancer or tumor growth, by administering to a subject in need thereof a composition comprising a therapeutically or prophylactically effective amount of a compound that downregulates DDX3, for example a fused diimidazodiazepine ring compound or a pharmaceutically acceptable salt thereof. The invention also encompasses the use of DDX3 as a biomarker for diagnostic and treatment purposes, for example, to identify a hyperproliferative disorder susceptible to treatment by down regulation of DDX3.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: April 26, 2016
    Assignee: The Johns Hopkins University
    Inventors: Venu Raman, Guus Martinus Bol, Paul Joannes Van Diest
  • Patent number: 9259427
    Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.
    Type: Grant
    Filed: January 2, 2013
    Date of Patent: February 16, 2016
    Assignee: Rosemont Pharmaceuticals LTD
    Inventors: Carl Tierney, Stacey Powell, Peter Braybrooke, Geraint Jones
  • Patent number: 9241995
    Abstract: The invention relates to 10H-benzo[g]pteridine-2,4-dione derivatives, to the production thereof, and to the use thereof.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: January 26, 2016
    Assignee: TRIOPTOTEC GMBH
    Inventors: Tim Maisch, Andreas Späth
  • Patent number: 9089548
    Abstract: The present invention relates to a composition consisting of Vitamin C, L-glutamine, L-cystine or L-cysteine, riboflavin, succinic acid, fumaric acid, coenzyme Q10, and niacin. The present invention relates further to the use of the composition for minimizing the cell-damaging effect of radicals and harmful forms of oxygen, in particular of oxygen radicals or reactive oxygen species. The present invention relates to a composition comprising Vitamin C, L-glutamine, L-cystine or L-cysteine, riboflavin, succinic acid, fumaric acid, coenzyme Q10, and niacin, wherein the composition is administered in a concentration ranging from 10 to 20 mg/kg body weight. The present invention relates further to the composition for use in the treatment and/or prevention of radical and harmful forms of oxygen derived diseases, in particular of oxygen radical or reactive oxygen species derived diseases. The present invention relates further to the composition as a food supplement or dietary supplement.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: July 28, 2015
    Assignee: Tima Foundation
    Inventor: Haruhiko Inufusa
  • Publication number: 20150136638
    Abstract: The present invention relates to a method for preparing a syrupy product comprising vitamins, said method comprising the following steps: a) inerting all the apparatuses implemented in the method b) inserting sugar syrup into said apparatuses and adding vitamins under inert atmosphere; c) adding dehydrated and deoxygenated glucose under inert atmosphere; d) deoxygenating the syrupy product formed in this way; e) packaging the syrupy product under inert atmosphere.
    Type: Application
    Filed: January 29, 2013
    Publication date: May 21, 2015
    Applicant: LaboratoiresUrgo
    Inventors: Franck Eymard, Pierre Gabiot, Romain Brenon, Michel Lamoise
  • Publication number: 20150132410
    Abstract: The invention provides compositions for the prevention and treatment of the symptoms of alcoholic beverage-induced hangover syndrome, related kits and methods of using the compositions and kits.
    Type: Application
    Filed: November 12, 2014
    Publication date: May 14, 2015
    Inventor: Michael M. Jacobs
  • Publication number: 20150093454
    Abstract: The present invention relates to a composition comprising alfa-lipoic acid, or a salt or complex thereof, and honokiol, wherein the weight quantity of said honokiol is between 1% and 30% with respect to the total weight of honokiol and alfa-lipoic acid.
    Type: Application
    Filed: April 19, 2013
    Publication date: April 2, 2015
    Inventors: Carlo Terruzzi, Fabio Terruzzi
  • Publication number: 20150080407
    Abstract: The present invention relates to a composition containing riboflavin and a sesamin-class compound(s). This composition may incorporate a sesamin-class compound (s) in such an amount that the proportion (weight ratio) of its total quantity to the total quantity of riboflavin taken as unity is no more than 4.5, and it has the advantage that the analgesic and anti-fatigue actions of riboflavin are synergistically improved by ingestion of riboflavin in combination with a sesamin-class compound(s). The composition of the present invention provides compositions, in particular, pharmaceuticals as well as foods and beverages that are safe to humans, animals, etc. and can therefore be ingested for a continued period, and which have far superior effects to those of conventional foods having an analgesic or anti-fatigue action.
    Type: Application
    Filed: November 24, 2014
    Publication date: March 19, 2015
    Applicant: SUNTORY HOLDINGS LIMITED
    Inventors: Daisuke TAKEMOTO, Norifumi TATEISHI, Yoshiko ONO, Kayo SAITO, Akifumi MAEDA
  • Publication number: 20150079149
    Abstract: A strip, which is both edible and dissolvable, is provided comprising a film and a dosage of at least 2% of the reference daily intake (RDI) of at least one dietary supplement for malnutrition or to prevent/treat alcohol induced hangovers. A method for treating malnutrition and/or preventing and treating alcohol-induced hangovers using a dissolvable orally administered strip.
    Type: Application
    Filed: November 19, 2014
    Publication date: March 19, 2015
    Inventor: Alessandra Grassi
  • Publication number: 20150023941
    Abstract: The present invention provides compositions comprising sugar, cysteine, and/or sugar-cysteine products, methods of preparing the same, and/or using the same.
    Type: Application
    Filed: October 6, 2014
    Publication date: January 22, 2015
    Inventors: David Bagley, Scott Momii, Scott Nagasawa, Herbert T. Nagasawa
  • Publication number: 20150025032
    Abstract: A pharmaceutical dosage system comprising (a) an effective amount of one or more of Doxylamine, an analog thereof, a derivative thereof, a prodrug thereof, a metabolite thereof and/or a salt thereof; (b) an effective amount of one or more of (i) Pyridoxine, (ii) an analog thereof, (iii) a derivative thereof, (iv) a prodrug thereof, (v) a metabolite thereof and (vi) a salt of any of (i)-(v); and (c) an effective amount of one or more compounds of formula (I) wherein R is H, PO3? or The system exhibits an improved pharmacokinetic profile relative to the current Diclectin®/Diclegis® formulation and is useful for example for the alleviation of the symptoms of nausea and vomiting, for example in the case of nausea and vomiting of pregnancy (NVP).
    Type: Application
    Filed: March 27, 2014
    Publication date: January 22, 2015
    Applicant: Duchesnay Inc.
    Inventors: Manon VRANDERICK, Jean-Luc ST-ONGE, Michele GALLO, Éric GERVAIS
  • Publication number: 20150017260
    Abstract: A nutritional supplement composition for treating nutritional deficiencies caused by a medical condition in subjects is disclosed. The present application further discloses a method of using a nutritional supplements composition for treating a subject with complications resulting from sickle cell anemia. The method comprises administering to a subject an effective amount of the nutritional supplement.
    Type: Application
    Filed: July 28, 2014
    Publication date: January 15, 2015
    Inventors: Jacqueline M. Hibbert, Jonathan K. Stiles, Kayellen Umeakunne, Hyacinth I. Hyacinth
  • Publication number: 20140370091
    Abstract: An enteric preparation having a film-forming property and acid resistance is provided by using a simple and efficient method without using a special cooling apparatus. More specifically, provided is a method for producing an aqueous enteric coating liquid including the steps of: partially neutralizing an aqueous suspension including a cellulosic enteric material with an aqueous alkali solution, and mixing the partially-neutralized aqueous suspension with a plasticizer. Also provided is a solid preparation including a core including a drug and a coating portion obtained by coating the core with the produced aqueous enteric coating liquid. Further, provided is a method for producing a solid preparation, including respective steps in the method for producing an aqueous enteric coating liquid and a step of coating a core including a drug with the produced aqueous enteric coating liquid.
    Type: Application
    Filed: May 28, 2014
    Publication date: December 18, 2014
    Applicant: Shin-Etsu Chemical Co., Ltd.
    Inventors: Shingo Kikuchi, Takafumi Hoshino, Yuichi Nishiyama
  • Publication number: 20140343480
    Abstract: Various agents and additives for cross-linking treatments are identified in disclosed studies. The characteristics of the various agents and additives may be advantageously employed in formulations applied in cross-linking treatments of the eye. In some embodiments, riboflavin is combined with Iron(II) to enhance the cross-linking activity generated by the riboflavin. In other embodiments, cross-linking treatments employ an Iron(II) solution in combination with a hydrogen peroxide pre-soak. In yet other embodiments, 2,3-butanedione is employed to increase the efficacy of corneal cross-linking with a photosensitizer, such as riboflavin. In further embodiments, folic acid is employed in combination with a photosensitizer, such as riboflavin, to enhance cross-linking activity. In yet further embodiments, 2,3-butanedione, folic acid, a quinoxaline, a quinoline, dibucaine, Methotrexate, menadione, or a derivative thereof is applied as a cross-linking agent.
    Type: Application
    Filed: May 19, 2014
    Publication date: November 20, 2014
    Applicant: AVEDRO, INC.
    Inventors: Pavel Kamaev, Marc D. Friedman, Evan Sherr, David Muller
  • Patent number: 8889194
    Abstract: Disclosed is a compound and methods for use by an individual attempting to reduce or cease tobacco smoking or one exposed to environmental tobacco smoke. The compound includes a first component blocking nicotine receptor sites to reduce nicotine cravings or withdrawal symptoms, a second component increasing serotonin levels and acting synergistically with the first component to reduce nicotine cravings or withdrawal symptoms, assisting in maintaining body weight and reducing increased stress and anxiety, and a third component acting synergistically with the first and/or second component to reduce nicotine cravings or withdrawal symptoms, maintain body weight, and/or reduce increased stress and anxiety. The third component comprises a supplement that replenishes depleted body substance(s), repairs damaged body substance(s), and/or ameliorates the impaired function of body substance(s). Some combination of the first, second, and third component alters the perceived taste of tobacco smoke.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: November 18, 2014
    Inventor: Harlan Clayton Bieley
  • Publication number: 20140309186
    Abstract: A method, computer-readable medium, and system for identifying one or more metabolites associated with a disease, comprising: comparing gene expression data from diseased cells to gene expression data from control cells in order to deduce genes that are differentially-regulated in the diseased cells relative to the control cells; based on enzyme function and pathway data for all human metabolites that utilize the genes that are differentially-regulated in the disease cells, identifying one or more metabolites whose intracellular levels are higher or lower in diseased cells than in control cells, and thereby associating the one or more metabolites with the disease.
    Type: Application
    Filed: June 24, 2014
    Publication date: October 16, 2014
    Inventors: Jeffrey Skolnick, Adrian K. Arakaki, John McDonald, Roman Mezencev, Nathan Bowen
  • Publication number: 20140303173
    Abstract: An improved formulation of an ophthalmic composition contains riboflavin, as cross-linking agent of corneal collagen, administered by corneal iontophoresis, able to guarantee an increased capacity of permeation of riboflavin of the corneal stroma and therefore greater therapeutic efficacy in the treatment of keratoconus.
    Type: Application
    Filed: October 24, 2012
    Publication date: October 9, 2014
    Inventors: Fulvio Foschini, Marcello Stagni, Giulio Luciani, Pierre Roy
  • Publication number: 20140212459
    Abstract: The invention relates to 10H-benzo[g]pteridine-2,4-dione derivatives, to the production thereof, and to the use thereof.
    Type: Application
    Filed: June 22, 2012
    Publication date: July 31, 2014
    Inventors: Tim Maisch, Andreas Späth
  • Publication number: 20140200220
    Abstract: The present disclosure relates to 10H-benzo[g]pteridine-2,4-dione derivatives, to the production thereof, and to the use thereof.
    Type: Application
    Filed: June 22, 2012
    Publication date: July 17, 2014
    Inventors: Tim Maisch, Andreas Spath
  • Publication number: 20140148398
    Abstract: Compounds useful for the treatment of giardiasis are described.
    Type: Application
    Filed: October 12, 2011
    Publication date: May 29, 2014
    Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Service, UNIVERSITY OF MARYLAND, COLLEGE PARK
    Inventors: Wei Zheng, Catherine Chen, Juan Jose Marugan, Noel Southall, Christopher P. Austin, Andrey Galkin, Liudmila Kulakova, Osnat Herzberg
  • Publication number: 20140147514
    Abstract: A process for extracting vitamins and minerals from a first plant matter(s) is disclosed wherein the said first plant matter(s) is treated with acidic matter followed by extraction with water. Said treatment converts the water-insoluble vitamins and minerals into water-soluble forms leading to a more comprehensive extraction with better yields of the plant constituents. Suitable selection of the first and second plant matter(s) and their proportions yields an extract that is a ready-made formulation of the desired vitamins and minerals in RDA quantities. Other advantages are reduced processing times and processing steps. Extraction of guava fruits, guava leaves, holy basil leaves, lemon peels, amla fruits, annato seeds, Wrightia tinctoria, Lantana camara, bamboo shoots, mustard seeds, and curry leaves is described.
    Type: Application
    Filed: July 30, 2012
    Publication date: May 29, 2014
    Inventors: Ramaswamy Rajendran, Kamala Rajendran
  • Publication number: 20140141107
    Abstract: A process for the extraction of the B group of vitamins from a first plant matter is disclosed wherein, prior to the said extraction operation, the first plant matter is treated with a second plant matter comprising acidic compounds. The acidification converts the said vitamins into more water-soluble forms and increases the yield thereof. In one example, the first plant matter comprises guava fruit matter, holy basil leaves and lemon peels, the two last-mentioned plant species being the source of the acidic compounds. The vitamins extracted and the proportions thereof can be controlled by a suitable choice of the plant species constituting the first and second plant matters and their quantities such as to give a substantially ready formulation conforming to RDA values or other requirements. The vitamins extracted are B1, B2, B3, B5, B6 and B9, the above combination of plant matters giving higher yield than others. The process is of general applicability to other plant constituents.
    Type: Application
    Filed: July 30, 2012
    Publication date: May 22, 2014
    Inventors: Ramaswamy Rajendran, Kamala Rajendran
  • Patent number: 8728535
    Abstract: In one embodiment of the present invention, a pharmaceutically-acceptable single-dosage formulation consists essentially of about 500 mg of vitamin C; about 400 IUs of vitamin D3; about 125 IUs of vitamin E; about 25 mg of vitamin B1; about 3.4 mg of vitamin B2; about 35 mg of niacin; about 35 mg of vitamin B6; about 1.25 mg of folic acid; about 70 mcg of vitamin B12; about 5 mg of pantothenic acid; about 75 mcg of biotin; about 35 mg of magnesium; about 35 mg of zinc; about 1 mg of copper; about 125 mcg of selenium; about 150 mcg of chromium; about 10 mg of alpha lipoic acid; about 35 mg of co-enzyme Q-10; about 400 mcg of lutein; about 125 mcg of lycopene; and at least one or more excipients.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: May 20, 2014
    Assignee: Vertical Pharmaceuticals, LLC
    Inventors: Steven A. Squashic, Kevin M. Hudy, David C. Purdy
  • Publication number: 20140127171
    Abstract: Methods of treating chronic post-traumatic encephalopathy (PTE) using regenerative approaches is described. In one embodiment, molecules with capability of stimulating endogenous neural stem cells is provided. In another embodiment, cell therapeutics are provided capable of addressing angiogenic deficits in patients suffering from PTE. In another embodiment, cells are utilized to induce activation of endogenous progenitor cells in the central nervous system of PTE patients. Furthermore, low level laser irradiation is disclosed as a means of treatment of PTE either through direct administration to CNS tissue for stimulation of endogenous progenitor cells and reparative processes, or together with administration of exogenous stem cells, whether autologous or allogeneic. In a further embodiment exogenous stem cells are pretreated with laser prior to administration.
    Type: Application
    Filed: November 4, 2013
    Publication date: May 8, 2014
    Inventors: Roger Nocera, James Eaker
  • Publication number: 20140128403
    Abstract: Use of 10H-benzo[g]pteridine-2,4-dione derivatives as photosensitizers in the inactivation of microorganisms.
    Type: Application
    Filed: June 22, 2012
    Publication date: May 8, 2014
    Inventors: Tim Maisch, Andreas Späth
  • Patent number: 8691299
    Abstract: Disclosed is an ingestible insect repellent composition and method utilizing a mixture of vitamins and extracts of lemon, coffee and/or peppermint as active insect deterrent. The composition may be diluted for easier intake into water, juices, milk, soda, mixed drinks and other beverages. Exemplary embodiments disclosed herein may include creating a premix capable of providing up to 100% of the suggested daily intake of specific Vitamin when diluted in any appropriate beverage. Exemplary embodiments may be utilized to repel insects for hours after ingestion in both humans and animals. The exemplary embodiments may provide this repellant without the harmful effects of other chemicals and repellants.
    Type: Grant
    Filed: April 4, 2011
    Date of Patent: April 8, 2014
    Inventors: Deveral Bodden, Ana Carro
  • Patent number: 8633192
    Abstract: Compositions and their use in the treatment or prevention of hyperglycemia and related diseases or disorders are disclosed.
    Type: Grant
    Filed: December 14, 2007
    Date of Patent: January 21, 2014
    Assignee: TIMA Foundation
    Inventors: Markus Matuschka-Greiffenclau, Haruhiko Inufusa
  • Patent number: 8614184
    Abstract: A formulation of human chorionic gonadotropin (HCG) for promoting weight loss comprising reconstituted HCG in an amount sufficient to promote weight loss; at least one vitamin selected from the group consisting of: vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B7, vitamin B9, and vitamin B12; and at least one dietary supplement selected from the group consisting of: an amino acid, inositol, choline chloride, and L-carnitine.
    Type: Grant
    Filed: September 22, 2010
    Date of Patent: December 24, 2013
    Inventor: Ronald P. Santasiero
  • Publication number: 20130337096
    Abstract: The present document describes a buccal delivery dosage form for administration of an active ingredient, including pharmaceutically, pharmacologically, or biologically active ingredients, in the mouth of a subject. The buccal delivery dosage form by-passes the gastrointestinal tract metabolism. The buccal delivery dosage form may comprise chemical permeation enhancers, excipients, texture modulators, and active ingredients.
    Type: Application
    Filed: February 28, 2012
    Publication date: December 19, 2013
    Applicant: TECHNOLOGIES KHLOROS INC.
    Inventor: Marc Purcell
  • Patent number: 8609629
    Abstract: The present invention relates to methods of co-administration of various vitamin and mineral compositions, and in a specific embodiment, said methods comprise co-administering one composition comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D3, vitamin E, iron, magnesium and zinc, and a second composition comprising omega-3 fatty acids such as DHA, to supplement the nutritional needs of individuals within physiologically stressful states; and kits provided for co-administration of various vitamin and mineral compositions, and in a specific embodiment, said kits comprise one composition comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D3, vitamin E, iron, magnesium and zinc, and a second composition comprising omega-3 fatty acids such as DHA, to supplement the nutritional needs of individuals within physiologically stressful states.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: December 17, 2013
    Assignee: Evertt Laboratories, Inc.
    Inventors: John A. Giordano, Charles J. Balzer
  • Publication number: 20130331362
    Abstract: An ophthalmic solution is provided. The ophthalmic solution includes an ultraviolet-A absorber and an ultraviolet-B absorber. The ophthalmic solution has a viscosity of between about 1 and 100 cps. The ophthalmic solution can be used to absorb ultraviolet radiation in the eye.
    Type: Application
    Filed: June 6, 2012
    Publication date: December 12, 2013
    Inventor: Brian J. Smith
  • Patent number: 8580789
    Abstract: Provided herein are methods of protecting all or a portion of the optic nerve fiber layer within the optic nerve/lamina cribrosa (ONLC) complex in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of an agent that results in crosslinking of collagen in the indiviudal's peripapillary sclera, thereby stiffening the individual's peripapillary sclera and protecting all or a portion of the optic nerve fiber layer within the ONLC of the individual. In a particular embodiment, the invention is directed to methods of treating glaucoma in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of an agent that results in crosslinking of collagen in the indiviudal's peripapillary sclera, thereby stiffening the individual's peripapillary sclera and treating the glaucoma in the individual.
    Type: Grant
    Filed: April 2, 2008
    Date of Patent: November 12, 2013
    Assignees: The Cleveland Clinic Foundation
    Inventors: Ronald R. Krueger, William J. Dupps, Stephen Trokel, Ivey Thornton
  • Publication number: 20130267528
    Abstract: Trans-epithelial osmotic collyrium for the treatment of keratoconus by corneal cross-linking with UV rays, of the type consisting of a riboflavin-based solution and an absorption enhancement adjuvant consisting of benzalkonium chloryde (BAC). The solution has a hypoosmolarity degree ranging between ?70% and ?30% over an isotonic solution and contains a BAC concentration accordingly ranging between 0.005% and 0.035%.
    Type: Application
    Filed: July 4, 2011
    Publication date: October 10, 2013
    Applicant: AVEDRO, INC.
    Inventor: Roberto Pinelli
  • Publication number: 20130261127
    Abstract: A composition can include a plurality of active ingredients such as pyruvate, niacin, riboflavin, lipoic acid, and amidated glycine. The concentration by weight of the first active ingredient (pyruvate) in the composition can be greater than the concentration by weight of each one of the other active ingredients. The composition can affect ATP and Krebs efficiency when ingested by an animal.
    Type: Application
    Filed: May 30, 2013
    Publication date: October 3, 2013
    Inventor: Kevin Meehan
  • Publication number: 20130245598
    Abstract: The preparation and use of photosensitizer-containing nanoparticles including photoactive vitamin-containing nanoparticles as photodynamic antimicrobial agents are disclosed for tissue repair including the treatment of chronic wounds.
    Type: Application
    Filed: July 21, 2011
    Publication date: September 19, 2013
    Inventor: Patty Fu-Giles
  • Patent number: 8535659
    Abstract: The present invention relates to different nutritional supplements to be administered to, or taken by, pregnant women during the first, second and third trimesters of pregnancy.
    Type: Grant
    Filed: May 21, 2009
    Date of Patent: September 17, 2013
    Assignee: Argent Development Group, LLC
    Inventors: John C. Morrison, Kenneth R. Greathouse
  • Patent number: 8535660
    Abstract: The present invention relates to different nutritional supplements to be administered to, or taken by, pregnant women during the first, second and third trimesters of pregnancy.
    Type: Grant
    Filed: November 7, 2011
    Date of Patent: September 17, 2013
    Assignee: Argent Development Group, LLC
    Inventors: John C. Morrison, Kenneth R. Greathouse
  • Publication number: 20130183277
    Abstract: Provided are compositions and methods for increasing patient CD4+ cell count while undergoing treatment for immune-mediated disease, cancer, heart disease, neurodegenerative disease, or infectious disease by administering to the patient a nutrient composition including, inter alia, alpha lipoic acid, acetyl L-carnitine, and N-acetyl-cysteine.
    Type: Application
    Filed: December 19, 2012
    Publication date: July 18, 2013
    Inventor: Jon D. Kaiser
  • Publication number: 20130171120
    Abstract: This invention relates to a composition that contains quercetin, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B12, vitamin C, caffeine, epigallocatechin gallate, epicatechin, epicatechin gallate, and epigallocatechin.
    Type: Application
    Filed: November 16, 2012
    Publication date: July 4, 2013
    Applicant: THE FRS COMPANY
    Inventor: THE FRS COMPANY
  • Publication number: 20130156855
    Abstract: One example embodiment includes a chemical composition for the treatment of acne. The chemical composition includes pantothenic acid and L-Carnitine.
    Type: Application
    Filed: December 16, 2011
    Publication date: June 20, 2013
    Inventor: Aviv Ben-Menachem
  • Publication number: 20130129695
    Abstract: The invention provides methods for treating or inhibiting infection by Clostridium difficile in a subject in need of such treatment, comprising administering an effective amount of a compound binding to a CD3299 riboswitch, as well as assays for identifying compounds useful in such treatment, and the use of particular compounds in such treatment.
    Type: Application
    Filed: February 4, 2011
    Publication date: May 23, 2013
    Inventor: Kenneth Blount
  • Patent number: 8383120
    Abstract: Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.
    Type: Grant
    Filed: January 13, 2012
    Date of Patent: February 26, 2013
    Assignee: The Mathilda and Terence Kennedy Institute of Rheumatology Trust
    Inventors: Marc Feldmann, Ravinder N. Maini
  • Patent number: 8372825
    Abstract: Skin compositions comprising, hydrocortisone; allantoin; and a water-based vehicle that is essentially free of petroleum jelly, mineral oil and wax; and related method for protecting, healing and/or soothing the skin comprising: applying an effective amount of a cosmetic preparation selected from the group consisting of hand cream, foot cream, body cream, lip cream, lip gloss, lip stick, gel, balm and lotion to the skin surface; wherein said cosmetic preparation includes a skin composition made of hydrocortisone; allantoin; and a water-based vehicle that is essentially free of petroleum jelly, mineral oil and wax; and said effective amount is enough to protect, heal and/or soothe the skin surface.
    Type: Grant
    Filed: August 13, 2009
    Date of Patent: February 12, 2013
    Inventor: Norman Turkowitz
  • Publication number: 20130029998
    Abstract: The present invention generally relates to methods of detecting and profiling progression of the risk of neurodegenerative diseases in a subject. In one embodiment, the method includes isolating a stem cell from cerebrospinal fluid of the subject and determining the level of H3K27 methylation within the stem cell. The subject is determined to have an increased risk of developing the neurodegenerative disease if the level of H3K27 methylation is elevated. In various embodiments, the neurodegenerative disease is Alzheimer's Disease, Parkinson's Disease or Amyotrophic Lateral Sclerosis.
    Type: Application
    Filed: April 21, 2011
    Publication date: January 31, 2013
    Inventors: Chandra Shekhar Mayanil, Shunsuke Ichi, Tadanori Tomita
  • Publication number: 20120295903
    Abstract: The present invention relates novel flavin derivatives and other flavin derivatives, their use and compositions for use as riboswitch ligands and/or anti-infectives. The invention also provides method of making novel flavin derivatives.
    Type: Application
    Filed: June 30, 2010
    Publication date: November 22, 2012
    Inventors: Kenneth F. Blount, Philip D.G. Coish, Brian R. Dixon, Jayhyuk Myung, David Osterman, Phil Wickens, Stephanie Avola, Nick Baboulas, Angelica Bello, Judd Berman, Harpreet Kaur, David Moon, Vinh Pham, Andrew Roughton, Jeffrey Wilson, Jeffrey A. Leiby, Dennis Underwood, Paul Adrian Aristoff, Heinrich J. Schostarez, Robert A. Chrusciel, Thomas R. Belliotti, Bruce R. Evans, Frank C. Sciavolino, Manuel A. Navia
  • Patent number: 8309535
    Abstract: The invention describes methods and compositions for alleviating recurrent medical afflictions for which anxiety may cause or exacerbate the affliction. A subject suffering from the affliction is treated with a combination of a pharmaceutical that enhances learning, and a second pharmaceutical recognized to be useful for treatment of the affliction. Representative afflictions include insomnia, erectile dysfunction, female sexual dysfunction, neuropathic pain, attention deficit disorder, and depression.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: November 13, 2012
    Inventors: Jason P. McDevitt, Michael Davis